Detalhe da pesquisa
1.
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia.
N Engl J Med
; 388(4): 319-332, 2023 01 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-36511784
2.
Sustained remissions in CLL after frontline FCR treatment with very-long-term follow-up.
Blood
; 142(21): 1784-1788, 2023 11 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-37595283
3.
Plain language summary of zanubrutinib or ibrutinib in chronic lymphocytic leukemia that is resistant to treatment or has come back after treatment.
Future Oncol
; 20(12): 717-726, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38088119
4.
Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials.
Br J Haematol
; 196(4): 947-953, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34865212
5.
Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis.
Cancer
; 127(18): 3381-3389, 2021 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34138471
6.
Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy.
Blood
; 134(22): 1951-1959, 2019 11 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-31537528
7.
ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
Future Oncol
; 16(10): 517-523, 2020 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-32207333
8.
Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study.
Cancer
; 125(14): 2474-2487, 2019 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30920645
9.
Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis.
Cancer
; 125(15): 2579-2586, 2019 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30985931
10.
Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis.
Br J Haematol
; 184(4): 558-569, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30506764
11.
Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis.
Am J Hematol
; 94(5): 554-562, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30767298
12.
Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000.
Cancer
; 124(12): 2534-2540, 2018 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29645075
13.
Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials.
Br J Haematol
; 182(4): 504-512, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29873072
14.
Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia.
Blood
; 127(3): 303-9, 2016 Jan 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-26492934
15.
Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Blood
; 128(4): 504-7, 2016 07 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-27235138
16.
Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL.
Blood
; 127(20): 2411-5, 2016 05 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-26968534
17.
Acute lymphoblastic leukemia in adolescents and young adults.
Cancer
; 123(13): 2398-2403, 2017 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28328172
18.
Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship.
Cancer
; 123(4): 609-616, 2017 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27763690
19.
Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
Cancer
; 123(2): 294-302, 2017 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27602508
20.
Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease.
Cancer
; 123(3): 459-467, 2017 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27696391